These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 32089674)

  • 1. Reference Gene and Protein Expression Levels in Two Different NAFLD Mouse Models.
    Araujo LCC; Bordin S; Carvalho CRO
    Gastroenterol Res Pract; 2020; 2020():1093235. PubMed ID: 32089674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-fat diet overfeeding promotes nondetrimental liver steatosis in female mice.
    Arisqueta L; Navarro-Imaz H; Labiano I; Rueda Y; Fresnedo O
    Am J Physiol Gastrointest Liver Physiol; 2018 Nov; 315(5):G772-G780. PubMed ID: 30095299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. iPLA2β deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling.
    Deng X; Wang J; Jiao L; Utaipan T; Tuma-Kellner S; Schmitz G; Liebisch G; Stremmel W; Chamulitrat W
    Biochim Biophys Acta; 2016 May; 1861(5):449-61. PubMed ID: 26873633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease.
    Li Z; Yang S; Lin H; Huang J; Watkins PA; Moser AB; Desimone C; Song XY; Diehl AM
    Hepatology; 2003 Feb; 37(2):343-50. PubMed ID: 12540784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
    Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
    Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Liraglutide protects against nonalcoholic fatty liver disease in ApoE knockout mice with high-fat diet and silenced Acrp30 by increasing AMPK].
    Zhao XY; Zhang LL; Suolang QZ; Yang GY; Li L; Li SB; Chen WW
    Zhonghua Gan Zang Bing Za Zhi; 2014 Nov; 22(11):849-53. PubMed ID: 25531383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients.
    Teufel A; Itzel T; Erhart W; Brosch M; Wang XY; Kim YO; von Schönfels W; Herrmann A; Brückner S; Stickel F; Dufour JF; Chavakis T; Hellerbrand C; Spang R; Maass T; Becker T; Schreiber S; Schafmayer C; Schuppan D; Hampe J
    Gastroenterology; 2016 Sep; 151(3):513-525.e0. PubMed ID: 27318147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
    Hookman P; Barkin JS
    Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
    Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
    Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity-related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2.
    Baffy G; Zhang CY; Glickman JN; Lowell BB
    Hepatology; 2002 Apr; 35(4):753-61. PubMed ID: 11915020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of liver changes in ZSF1 rats, an animal model of metabolic syndrome.
    Borges Canha M; Portela-Cidade JP; Conceição G; Sousa-Mendes C; Leite S; Fontoura D; Moreira-Gonçalves D; Falcão-Pires I; Lourenço A; Leite-Moreira A; Pimentel-Nunes P
    Rev Esp Enferm Dig; 2017 Jul; 109(7):491-497. PubMed ID: 28593786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ubiquitin-Specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance, and Inflammation Through Sirt6.
    Luo P; Qin C; Zhu L; Fang C; Zhang Y; Zhang H; Pei F; Tian S; Zhu XY; Gong J; Mao Q; Xiao C; Su Y; Zheng H; Xu T; Lu J; Zhang J
    Hepatology; 2018 Nov; 68(5):1786-1803. PubMed ID: 29698567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperleptinemia Exacerbates High-Fat Diet-Mediated Atrial Fibrosis and Fibrillation.
    Fukui A; Ikebe-Ebata Y; Kondo H; Saito S; Aoki K; Fukunaga N; Shinohara T; Masaki T; Teshima Y; Takahashi N
    J Cardiovasc Electrophysiol; 2017 Jun; 28(6):702-710. PubMed ID: 28257569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Troxerutin improves hepatic lipid homeostasis by restoring NAD(+)-depletion-mediated dysfunction of lipin 1 signaling in high-fat diet-treated mice.
    Zhang ZF; Fan SH; Zheng YL; Lu J; Wu DM; Shan Q; Hu B
    Biochem Pharmacol; 2014 Sep; 91(1):74-86. PubMed ID: 25026599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARα-Deficient ob/ob Obese Mice Become More Obese and Manifest Severe Hepatic Steatosis Due to Decreased Fatty Acid Oxidation.
    Gao Q; Jia Y; Yang G; Zhang X; Boddu PC; Petersen B; Narsingam S; Zhu YJ; Thimmapaya B; Kanwar YS; Reddy JK
    Am J Pathol; 2015 May; 185(5):1396-408. PubMed ID: 25773177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction.
    Boland ML; Oldham S; Boland BB; Will S; Lapointe JM; Guionaud S; Rhodes CJ; Trevaskis JL
    World J Gastroenterol; 2018 Apr; 24(16):1748-1765. PubMed ID: 29713129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.